Targeting VCAM-1 with chimeric antigen receptor and regulatory T cell for abdominal aortic aneurysm treatment.

This study explores a novel immunotherapeutic approach using chimeric antigen receptor Treg cells targeting vascular cell adhesion molecule-1 (VCAM-1) to mitigate AAA progression. These findings suggest that CAR-Treg cell therapy could provide a promising, non-surgical treatment option for AAA patients, addressing a critical unmet need in cardiovascular disease management.

Researchers relied on Countstar Rigel S2 for cell-count and viability measurements in the study's cell samples before single-cell analysis in the 2025 Communications biology study.